December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

91.48 +1.16 (+1.28%)
Streaming Delayed Price Updated: 9:31 AM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
News headline image
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
The 5 Most Interesting Analyst Questions From Incyte’s Q3 Earnings Call
Incyte’s third quarter saw revenue and profit surpass Wall Street’s expectations, yet the market responded negatively. Management identified robust demand for key drugs Jakafi and Opzelura, alongside... 
Via StockStory
Topics Earnings
News headline image
Stay informed with the top movers within the S&P500 index on Monday. ↗
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday. 
Via Chartmill
News headline image
Earnings Scheduled For October 28, 2025 ↗
 
Via Benzinga
News headline image
Exploring Incyte's Earnings Expectations ↗
 
Via Benzinga
News headline image
Kenvue, IDEXX Laboratories, Freshpet And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
These S&P500 stocks have an unusual volume in today's session ↗
Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below. 
Via Chartmill
News headline image
Exploring the top movers within the S&P500 index during today's session. ↗
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
News headline image
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
INCY Q3 Deep Dive: Strong Product Momentum and Pipeline Reshaping Amid Strategic Refocus
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of... 
Via StockStory
News headline image
Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms ↗
Incyte Q3 revenue rose 20% to $1.37 billion, topping estimates, as Jakafi and Niktimvo fueled growth and the company raised its 2025 revenue outlook. 
Via Benzinga
Topics Intellectual Property
News headline image
These S&P500 stocks have an unusual volume in today's session ↗
Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below. 
Via Chartmill
News headline image
Nasdaq 100 Hits 26,000, Gold Falls Below $4,000: What's Moving Markets Tuesday? ↗
Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump-Xi meeting, and major tech earnings. 
Via Benzinga
Topics Economy
News headline image
Why Incyte (INCY) Stock Is Trading Lower Today
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 4.2% in the morning session after the company reported underwhelming third-quarter 2025 financial results. 
Via StockStory
News headline image
Incyte (INCY) Q3 2025 Earnings Call Transcript ↗
Incyte (INCY) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views ↗
The company delivered significantly better-than-expected third-quarter sales and earnings, but shares took a premarket hit. 
Via Investor's Business Daily
Topics Government
News headline image
Incyte Corp (NASDAQ:INCY) Reports Strong Q3 2025 Earnings, Beating Estimates ↗
Incyte (INCY) Q3 2025 earnings beat expectations with $1.37B revenue and $2.26 EPS. Driven by Jakafi and Opzelura growth, the company also raised its full-year 2025 guidance. 
Via Chartmill
Topics Earnings
News headline image
Incyte (NASDAQ:INCY) Reports Strong Q3
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share... 
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
From Incyte
Via Business Wire
News headline image
Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System
From Incyte and Enable Injections
Via Business Wire
News headline image
What To Expect From Incyte’s (INCY) Q3 Earnings
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings this Tuesday morning. Here’s what you need to know. 
Via StockStory
News headline image
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
From Incyte
Via Business Wire
News headline image
Eli Lilly's New Ebglyss Results Back Flexible Treatment Options For Atopic Dermatitis ↗
Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for Olumiant in hair regrowth. 
Via Benzinga
News headline image
INCYTE CORP (NASDAQ:INCY) Presents a Value Investing Opportunity with Strong Fundamentals ↗
INCYTE CORP (INCY) appears undervalued with strong profitability and a healthy balance sheet. Its low P/E and high ROE suggest a potential value investing opportunity. 
Via Chartmill
News headline image
These S&P500 stocks are gapping in today's session ↗
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Monday. Discover the gap up and gap down stocks in the S&P500 index. 
Via Chartmill
News headline image
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
From Incyte
Via Business Wire
News headline image
Incyte (INCY) Stock Is Up, What You Need To Know
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 1.5% in the afternoon session after the company announced Health Canada's approval of its Opzelura cream for treating atopic... 
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
From Incyte
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.